Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2989-2994

  McCabe, Michael T ^a   Graves, Alan P ^b   Ganji, Gopinath ^a   Diaz, Elsie ^b   Halsey, Wendy S ^b   Jiang, Yong ^b   Smitheman, Kimberly N ^a   Ott, Heidi M ^a   Pappalardi, Melissa B ^a   Allen, Kimberly E ^b   Chen, Stephanie B ^b   Pietra III, Anthony Della ^a   Dul, Edward ^b   Hughes, Ashley M ^b   Gilbert, Seth A ^a   Thrall, Sara H ^b   Tummino, Peter J ^a   Kruger, Ryan G ^a   Brandt, Martin ^b   Schwartz, Benjamin ^b   Creasy, Caretha L ^a   more..

^a Oncology Research and Development   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; HISTONE; HISTONE H3 ON LYSINE 27; HISTONE METHYLTRANSFERASE; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CATALYSIS; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; EXON; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; HISTONE METHYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ALANINE; AMINO ACID SEQUENCE; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCINE; HETEROZYGOTE; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LYMPHOMA, B-CELL; LYSINE; METHYLATION; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 84863165348     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1116418109     Document Type: Article

References (40)

1. Morin RD, et al. (2011) Frequent mutation of histone-modifying genes in non- Hodgkin lymphoma. Nature 476:298-303.
2. Bödör C, et al. (2011) EZH2 Y641 mutations in follicular lymphoma. Leukemia 25:726-729.
3. Morin RD, et al. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181-185.
4. Gui Y, et al. (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43:875-878.
5. Fathi AT, Abdel-Wahab O (2012) Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol 2012: 469592.
6. Stransky N, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-1160.
7. Figueroa ME, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567.
8. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 16:2893-2905. (Pubitemid 35334738)
9. Müller J, et al. (2002) Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111:197-208. (Pubitemid 35292440)
10. Cao R, et al. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039-1043. (Pubitemid 35247314)
11. Barski A, et al. (2007) High-resolution profiling of histone methylations in the human genome. Cell 129:823-837. (Pubitemid 46802390)
12. Su IH, et al. (2003) Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 4(2):124-131.
13. Kamminga LM, et al. (2006) The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107:2170-2179. (Pubitemid 43289403)
14. Majewski IJ, et al. (2010) Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. Blood 116:731-739.
15. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647(1-2):21-29.
16. Sneeringer CJ, et al. (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human Bcell lymphomas. Proc Natl Acad Sci USA 107:20980-20985.
17. Yap DB, et al. (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117:2451-2459.
18. Rogenhofer S, et al. (2012) Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int 109(3):459-465.
19. Chen C, et al. (2011) Abnormal histone acetylation and methylation levels in esophageal squamous cell carcinomas. Cancer Invest 29:548-556.
20. Dalgliesh GL, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463:360-363.
21. van Haaften G, et al. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41:521-523.
22. Friedman JM, et al. (2009) The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69:2623-2629.
23. Varambally S, et al. (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695-1699.
24. Bracken AP, et al. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323-5335. (Pubitemid 37279943)
25. Saramäki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T (2006) The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45:639-645. (Pubitemid 43727151)
26. Makishima H, et al. (2010) Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24:1799-1804.
27. Nikoloski G, et al. (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665-667.
28. Ernst T, et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722-726.
29. Gabay C, Ben-Bassat H, Schlesinger M, Laskov R (1999) Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Haematol 63:180-191. (Pubitemid 29406735)
30. Cai MY, et al. (2011) High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 17(1-2):12-20.
31. Cheng AS, et al. (2011) EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res 71:4028-4039.
32. Gal-Yam EN, et al. (2008) Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci USA 105: 12979-12984.
33. Velichutina I, et al. (2010) EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116:5247-5255.
34. Del Rizzo PA, et al. (2010) SET7/9 catalytic mutants reveal the role of active site water molecules in lysine multiple methylation. J Biol Chem 285:31849-31858.
35. Couture JF, Dirk LM, Brunzelle JS, Houtz RL, Trievel RC (2008) Structural origins for the product specificity of SET domain protein methyltransferases. Proc Natl Acad Sci USA 105:20659-20664.
36. Wigle TJ, et al. (2011) The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett 585:3011-3014.
37. Xiao B, et al. (2003) Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 421:652-656. (Pubitemid 36227675)
38. Wu H, et al. (2010) Structural biology of human H3K9 methyltransferases. PLoS ONE 5: e8570.
39. Zhang X, et al. (2003) Structural basis for the product specificity of histone lysine methyltransferases. Mol Cell 12(1):177-185. (Pubitemid 36957834)
40. Tamaru H, et al. (2003) Trimethylated lysine 9 of histone H3 is a mark for DNA methylation in Neurospora crassa. Nat Genet 34:75-79. (Pubitemid 36548794)